Amarin Corporation plc announced select preliminary unaudited 2025 financial highlights and key operational accomplishments.
The company achieved positive cash flow in the fourth quarter of 2025, earlier than forecasted, with a year-end cash balance of $303 million and no debt.
Key accomplishments in 2025 included market leadership in the U.S., successful European partnerships, and expansion into new markets like South Korea and Singapore.
Positive Cash Flow
Amarin achieved positive cash flow in Q4 2025, ahead of previous forecasts, and ended the year with $303 million in cash balance with no debt.
Market Leadership
Maintained market leadership in the U.S. for VASCEPA with over 50% share of IPE prescriptions by year-end 2025.
European Expansion
Established exclusive partnerships and secured pricing and reimbursement in European markets, with growth opportunities in Italy and new regulatory approvals in Austria and Slovenia.
Global Advances
Achieved increased demand in all markets with new approvals in South Korea and Singapore, emphasizing the global reach of Amarin's therapeutics.
Long-Term Growth
With over 25 million prescriptions globally, Amarin's VASCEPA/VAZKEPA franchise is well-positioned for long-term growth with approvals in over 50 countries and IP protection till 2039 in Europe.
- Amarin's 2025 results mark an inflection point, showcasing the company's strategic transformation and positive financial performance.
- The partnership with Recordati S.p.A. and significant OPEX savings further strengthen Amarin's operational efficiency and financial outlook.
- The company's global expansion and scientific advancements highlight its commitment to cardiovascular therapeutics and future growth opportunities.
Amarin Corporation plc's focus on operational excellence, financial stability, and global growth positions the company for continued success in 2026 and beyond.